Merck & Co., Inc. (MRK)
Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
Merck heads into Q4 earnings with strong Keytruda demand and new product launches, but declining estimates and M&A costs cloud the near-term outlook.
Why the Market Dipped But Merck (MRK) Gained Today
Merck (MRK) closed at $108.34 in the latest trading session, marking a +1.35% move from the prior day.
Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck's Non-Oncology Drugs Q4 Performance: What to Expect
MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.
What's Fueling The Rally In Merck Stock?
Merck (MRK)'s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence.
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck no longer in talks to buy Revolution Medicines, WSJ reports
Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.
Merck No Longer in Talks to Buy Revolution Medicines
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) concluded the recent trading session at $111.11, signifying a +1.52% move from its prior day's close.
Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?
Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.
